Total sleep time was increased in the Ambien CR group throughout the study. At week eight, patients reporting sleeping an average of 101 minutes more than baseline compared to placebo-treated patients who reported sleeping an average 64 minutes more (P<0.0001). On average, Ambien CR-treated patients reported falling asleep sooner and exhibited improved sleep maintenance based upon fewer nighttime awakenings and decreased wake time after sleep onset compared to placebo-treated patients (P<0.0001). In addition, patients reported improvements in secondary measures related to daytime functioning, including morning energy, morning concentration and sleep impact on daily activities. Thomas Roth, director of the Sleep Disorders and Research Center at Henry Ford Hospital, said: "The results of this study demonstrate that Ambien CR can be considered a viable treatment option for the insomnia major depressive disorder patients experience and help them get the good night's sleep they need to improve their next-day functioning."